LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Elenco Azioni・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

53.68 -1.2

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

53.02

Massimo

54.54

Metriche Chiave
By Trading Economics
Entrata	3M -102M
EPS	-1.17
Dipendenti	358
EBITDA	-7.6M -112M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+44.09% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-155M 5.4B
Apertura precedente	54.88
Chiusura precedente	53.68

Notizie sul Sentiment di mercato

By Acuity

33%

67%

67 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

34.81 / 38.24 Supporto e resistenza

Xenon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 mar 2026, 16:12 UTC

I principali Market Mover

Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner

Confronto tra pari

Modifica del prezzo

Xenon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

44.09% in crescita

Previsioni per 12 mesi

Media 78.37 USD 44.09%

Alto 100 USD

Basso 55 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Xenon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Xenon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

34.81 / 38.24Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

67 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.